Market open · 15-min delayed · as of 10:09 AM ET· Nasdaq · USD
Arbutus Biopharma (ABUS) Stock Checks
How ABUS measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.
The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).
2 / 17 qualify todayas of close, Nov 16, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
2
meet every gate today
BORDERLINE
2
within one input of the gate
FAILS
10
miss at least one gate
UNKNOWN
3
insufficient data to judge
✓passes·✕fails·~borderline·—unknown
Growth receipts arrive in a coming release
Value — six classic philosophies
Buffett Qualitydurable moat
~ Borderline›
✓PassesROE ≥ 15%(TTM through Sep 30, 2026)269.6% · ≥ 15.0%
✓PassesReturn on assets improving(fiscal 2025)−53.1% → −35.4%
✕FailsEarnings backed by cash (CFO > net income)(fiscal 2025)−$39.6M vs −$33.5M
✕FailsLeverage falling (long-term debt / assets)(fiscal 2025)We hold no record of long-term debt as a share of assets for both years for this company, so this signal could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
✓PassesCurrent ratio improving(fiscal 2025)8.15 → 15.73
Income & Dividend Safetycoverage over headline yield
— Insufficient inputs (1 of 5 known)›
✕FailsPays a dividend$0.00 · > 0
—Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
—Unknown — no dataCovered by free cash flow— · ≥ 1.20
—Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
—Unknown — no dataBalance sheet can sustain the payout— · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
Dividend Growthraises you can count on
— Insufficient inputs (1 of 6 known)›
✕FailsPays a dividend$0.00 · > 0
—Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
—Unknown — no dataNo dividend cut in the last 5 years—
✓PassesOff its 52-week high by 8–35% (a dip, not a collapse)25.0% · 8.0%–35.0%
✕FailsDip within its own normal pullback band0.31
✓PassesNot past where its dips have historically recovered from1.22
✕FailsA dip in an uptrend (above a rising 200-day)4.48
✕FailsHigher-low structure still intactstructure broken · no higher low
—Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
Reversal Evidencedaily close onlysigns the pullback is turning
✕ Fails›
✓PassesA bullish MACD cross within 10 sessions1.00 · ≤ 10.00
✕FailsReclaimed a rising 50-day EMA4.31
✕FailsPrinted a higher lowno
✕FailsA volume thrust on the turn (≥ 1.2× normal)0.97 · ≥ 1.20
✕FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)1.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page.
Not-a-Value-Trap Gatecheap for a good reason, not a broken one
✕ Fails›
✕FailsIn the cheap half of its own 5-year valuation range(through fiscal 2025)1.0×
✕FailsEarnings estimates not being cut−0.01
✓PassesReturns on capital not deteriorating−0.35
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
Quality Floorpasses the quality/value gate on this dip
✓ Qualifies›
✓PassesOperating profit is positive(TTM through Sep 30, 2026)$147.2M · > 0
✓PassesReturn on invested capital ≥ 10%(TTM through Sep 30, 2026)171.6% · ≥ 10.0%
—Not scored: see the reason belowA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)(TTM through Sep 30, 2026)Net debt / EBITDA cannot be read over non-positive EBITDA: the ratio flips sign, so a net-cash company prints a healthy-looking positive. Only the Altman Z half, shown beside this line, is measurable, so the test is left unscored rather than counted either way.−1.0×
✓PassesQuality score ≥ 5051.80 · ≥ 50.00
✓PassesRevenue growing over 5 years(fiscal 2020 to 2025)15.3% per year · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
Qualified Dipa pullback with receipts, not a falling knife
~ Borderline›
A research signal from published criteria, not a recommendation.
✕FailsDrawdown context25.0% off its 52-week high
✕FailsReversal evidence1 of 4 signals fired
✕FailsTrap gate1 of 3 held
✓PassesQuality floor4 of 5 held · 1 no data
Invalidation level (structure break): below this the dip's structure has broken$4.29
✕Fails50-day average above the 200-day (uptrend stack)4.46
✕Fails50-day average sloping up−0.07 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Relative Strengthoutperforming, ranked vs the universe
✕ Fails›
✕Fails3-month return in the top half of the universe0.33 · ≥ 0.50
✕Fails12-minus-1 momentum in the top half of the universe0.29 · ≥ 0.50
✕FailsRelative strength vs the S&P 500 improving−0.01 · > 0
✕FailsEarnings estimates being revised up−0.01
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
Momentum Triggera trigger you can see
✕ Fails›
✓PassesMACD above its signal line−0.15
✕FailsBack above the 50-day on a fresh cross (≤10 sessions)1.00
✕FailsHigher high and higher low (stair-stepping up)no higher high · no higher low
✕FailsA volume thrust on the move (≥ 1.2× normal)0.97 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page.
Volatility Regimecontext, not a signal
Context, not scored›
Average daily swing: elevated0.05
Volatility band width: mid-range0.75
Distance from its 52-week high: mid-range0.25
✓
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
!
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.
Common questions
How many investing rule sets does Arbutus Biopharma pass?
Arbutus Biopharma qualifies on 2 of 17 rule sets as of 2026-11-16, with 2 borderline and 10 failing.
Does Arbutus Biopharma meet the Graham Defensive criteria?
Arbutus Biopharma fails the Graham Defensive rule set as of 2026-11-16.
Does Arbutus Biopharma meet the Buffett Quality criteria?
Arbutus Biopharma is borderline on the Buffett Quality rule set as of 2026-11-16.
Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.